TRANSCODE THERAPEUTICS, INC. (RNAZ)

Import this data to Google Sheets with:

=jivedata("RNAZ","financials")

Full statements spill as a table. For one cell: =jivedata("RNAZ","Revenue") or =jivedata("RNAZ","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

TRANSCODE THERAPEUTICS, INC.

RNAZ • CIK 0001829635

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Research and Development Expense	$12,263.53	$9,706.358	$13,421.848	$17,437.152
Operating Income (Loss)	$-19,418.516	$-15,660.697	$-27,980.071	$-45,132.291
Operating Expenses	$19,418.516	$15,660.697	$27,980.071	$45,132.291
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	$-34,435.008	$-42,376.682
Deferred Income Tax Expense (Benefit)	—	—	$226.068	$226.068
Net Income (Loss) Attributable to Parent	$-18,546.095	$-16,754.971	$-34,661.076	$-42,834.359
Temporary Equity, Dividends, Adjustment	—	—	$1,610.211	$1,610.211
Net Income (Loss) Available to Common Stockholders, Basic	—	$-16,785.572	$-36,271.287	$-46,284.81
Weighted Average Number of Shares Outstanding, Basic	179,006	356,115	689,713	1,122,652
General and Administrative Expense	$7,154.986	$5,954.339	$5,771.063	$7,922.261
Business Combination, Acquisition Related Costs	—	—	$8,787.16	$8,787.16
Fair Value Adjustment of Warrants	—	$938.69	$9,277.321	$-223.188
Gain (Loss) on Disposition of Property Plant Equipment	—	$0.5	$0.5	$0.5
Foreign Currency Transaction Gain (Loss), before Tax	—	$-57.062	$-112.065	$-94.992
Investment Income, Interest	$5.285	$0.684	$79.198	$222.96
InterestExpenseNonoperating	—	—	$6.616	$6.616
Nonoperating Income (Expense)	$872.421	$-1,094.274	$-6,454.937	$2,755.609

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Property, Plant and Equipment, Net	$120.707	$51.574	$370.681	$322.809
Goodwill	—	—	$25,744.143	$25,744.143
Intangible Assets, Net (Excluding Goodwill)	—	—	$114,300	$114,300
Operating Lease, Right-of-Use Asset	$481.694	$37.731	$37.731	$37.731
Security Deposit	$111.856	$111.856	$111.856	$111.856
Assets	$5,169.701	$7,294.499	$162,398.689	$151,010.103
Liabilities	$3,528.887	$9,313.233	$10,518.687	$12,651.92
Cash and Cash Equivalents, at Carrying Value	$2,767.598	$5,811.064	$17,813.521	$8,383.393
Grants Receivable, Current	$360.229	—	$952.46	$0
Other Receivables, Net, Current	—	—	$0.638	$0.638
Prepaid Expense and Other Assets, Current	$1,687.846	$1,282.274	$919.44	$2,259.12
Assets, Current	$4,455.444	$7,093.338	$21,983.865	$10,643.151
Accounts Payable and Accrued Liabilities, Current	$3,051.259	$2,708.137	$3,494.22	$4,682.359
Contract with Customer, Liability, Current	$27.057	$25.408	$0	$63.947
Operating Lease, Liability, Current	$412.28	$38.291	$38.291	$38.291
Liabilities, Current	$3,490.596	$2,771.836	$3,494.22	$5,398.717
Business Combination, Contingent Consideration, Liability, Noncurrent	—	—	$6,364	$6,465
Deferred Income Tax Liabilities, Net	—	—	$226.068	$457.677
Liabilities, Noncurrent	—	$6,541.397	$7,024.467	$7,253.203
Common Stock, Value, Issued	$0.063	$0.103	$0.092	$0.101
Additional Paid in Capital	$48,057.095	$61,183.079	$108,198.366	$94,703.052
Retained Earnings (Accumulated Deficit)	$-46,416.344	$-63,201.916	$-97,862.992	$-122,398.191
Stockholders' Equity Attributable to Parent	$1,640.814	$-2,018.734	$10,335.466	$-27,694.917
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	1,435.916	1,215,670
Common Stock, Shares Authorized	290,000,000	290,000,000	290,000,000	290,000,000
Common Stock, Shares, Issued	627,448	1,029,095	916,968	1,011,595

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$-2,200.82	$3,043.466	$12,002.457	$1,008.578
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$2,767.598	$5,811.064	$17,813.521	$19,079.821
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$-18,546.095	$-16,754.971	$-34,661.076	$-42,834.359
Cash Acquired from Acquisition	—	—	$2.224	$2.224
Payments to Acquire Property, Plant, and Equipment	$35.609	$21.761	$6.66	$6.66
Net Cash Provided by (Used in) Investing Activities	$-35.609	$-21.761	$-4.436	$-4.436
Proceeds from Issuance of Convertible Preferred Stock	—	—	$22,668.324	$22,668.324
Proceeds from Issuance of Common Stock	$15,909.324	$16,401.174	$8,854.798	$8,854.798
Net Cash Provided by (Used in) Financing Activities	$15,909.324	$16,401.174	$31,523.122	$23,618.325
Interest Paid, Excluding Capitalized Interest, Operating Activities	$32.861	$16.629	$6.501	$6.501
Depreciation	$123.483	$90.894	$76.446	$97.434
Operating Lease, Right-of-Use Asset, Amortization Expense	$393.263	$443.963	$37.731	$37.731
Noncash Merger Related Costs	—	—	$6,836.992	$6,836.992
Share-based Payment Arrangement, Noncash Expense	$1,036.889	$1,699.999	$485.428	$485.428
Fair Value Adjustment of Warrants	—	$938.69	$9,277.321	$-223.188
Increase (Decrease) in Other Receivables	—	—	$0.638	$0.638
Increase (Decrease) in Prepaid Expense and Other Assets	$-362.912	$-405.573	$-477.261	$1,453.908
Increase (Decrease) in Deferred Revenue	$27.057	$-1.649	$-25.408	$63.947
Increase (Decrease) in Deposits Outstanding	$111.856	$111.856	$-111.856	$-111.856
IncreaseDecreaseInOperatingLeaseLiability	$-424.385	$-412.28	$-38.291	$-38.291
Net Cash Provided by (Used in) Operating Activities	$-18,074.535	$-13,335.947	$-19,516.229	$-22,605.311

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("RNAZ","financials")

Full statements spill as a table. For one cell: =jivedata("RNAZ","Revenue") or =jivedata("RNAZ","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.